Drug Trial Radar · NCT05135286
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
Last checked: Nov 19, 2026Latest source record: Aug 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
629
Actual
Start
Mar 15, 2022
Primary completion
Mar 13, 2025
Study completion Mar 13, 2025
Sponsor
- Lead sponsor
- Visus TherapeuticsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 45 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
Conditions
- Presbyopia
Interventions
BRIMOCHOL™ PFDrug
A single drop in each eye at a visit.
Carbachol PFDrug
A single drop in each eye at a visit.
VehicleDrug
A single drop in each eye at a visit.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in near VATime frame: Baseline Day 1
Locations
42 sites in 1 country. Site status is shown where the registry gives one.
Visus Therapeutics Investigative Site
Chandler, Arizona
Visus Therapeutics Investigative Site
Phoenix, Arizona
Visus Therapeutics Investigative Site
Sun City, Arizona
Visus Therapeutics Investigative Site
Glendale, California
Visus Therapeutics Investigative Site
Inglewood, California
Visus Therapeutics Investigative Site
Irvine, California
Visus Therapeutics Investigative Site
Mission Hills, California
Visus Therapeutics Investigative Site
Newport Beach, California
Visus Therapeutics Investigative Site
Pasadena, California
Visus Therapeutics Investigative Site
Santa Barbara, California
Visus Therapeutics Investigative Site
Littleton, Colorado
Visus Therapeutics Investigative Site
Danbury, Connecticut
Visus Therapeutics Investigative Site
Crystal River, Florida
Visus Therapeutics Investigative Site
Delray Beach, Florida
Visus Therapeutics Investigative Site
Fort Lauderdale, Florida
Visus Therapeutics Investigative Site
Jacksonville, Florida
Visus Therapeutics Investigative Site
Largo, Florida
Visus Therapeutics Investigative Site
Mt. Dora, Florida
Visus Therapeutics Investigative Site
Lake Villa, Illinois
Visus Therapeutics Investigative Site
Indianapolis, Indiana
Visus Therapeutics Investigative Site
Louisville, Kentucky
Visus Therapeutics Investigative Site
Bloomington, Minnesota
Visus Therapeutics Investigative Site
Kansas City, Missouri
Visus Therapeutics Investigative Site
St Louis, Missouri
Visus Therapeutics Investigative Site
Henderson, Nevada
Visus Therapeutics Investigative Site
Poughkeepsie, New York
Visus Therapeutics Investigative Site
Garner, North Carolina
Visus Therapeutics Investigative Site
West Fargo, North Dakota
Visus Therapeutics Investigative Site
Powell, Ohio
Visus Therapeutics Investigative Site
Portland, Oregon
Visus Therapeutics Investigative Site
Cranberry Township, Pennsylvania
Visus Therapeutics Investigative Site
Wilkes-Barre, Pennsylvania
Visus Therapeutics Investigative Site
Sioux Falls, South Dakota
Visus Therapeutics Investigative Site
Maryville, Tennessee
Visus Therapeutics Investigative Site
Memphis, Tennessee
Visus Therapeutics Investigative Site
Smyrna, Tennessee
Visus Therapeutics Investigative Site
Hurst, Texas
Visus Therapeutics Investigative Site
Lakeway, Texas
Visus Therapeutics Investigative Site
San Antonio, Texas
Visus Therapeutics Investigative Site
Draper, Utah
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.